Home
overview

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018.

  • Developments in ADMET and novel technologies determine the properties of a drug candidates in the preclinical stage of drug discovery.
  • In Research and Development ADMET properties are the principal cause for a candidate to fail at any stage of drug development.
  • ADMET studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.

     

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

 

Join our expert speaker panel to ensure you do not miss out on the latest developments, hear from:

  • Eric Blomme, Vice President, Global Pre-Clinical Safety,Senior Research Fellow, AbbVie
  • Sheila Annie Peters, Head, Translational Quantitative Pharmacology, Merck Serono
  • Nenad Manevski, DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB

and many more..

To see the full speaker line-up click here

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

The conference will be discussing new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling software to the validation of humanised mice models.

Topics include:

ADME/PK Optimisation for Drug Design and Discovery
Physiochemical Assessments
In Vitro to Human In Vivo Translation
Physiologically Based PK Modelling
DMPK, PBPK, PKPD
Pre-/Clinical Toxicity
Accurate First-in-Human Dose Predictions
Transporters, Bioavailability, Formulation
Metabolism Studies
Drug-Drug Interactions
Hazard and Safety Assessment
Predictive Toxicology
Preclinical Pharmacology Testing

To navigate the full conference programme click here 



 

 

Networking: Over 5 hours of Networking with your peers. Expand your community with every part of the industry and with the right people to benefit your company and develop your career.

CPD Certified: Continuing professional development (CPD) is a commitment by members to continually update their skills and knowledge to remain professionally competent. You can gain CPD points by attending this event!

Visit London: Summer is the perfect time to visit London, when you can visit Kew Gardens, roopftop brunches at Madison in St Pauls, attend the Wimbledon Tennis tournament and enjoy high-tea tea and scones, closer to the conference hotel you can also see the wonderful sights of Kensington, by visiting Kensington Palace, the historical Museums, or take a stroll in Kyoto Garden!
 

 

 

• DMPK Professionals
• Pharmacologists
• Computational Scientists
• Medicinal Chemists
• Statisticians
• Principle scientist
• Drug Metabolism Experts
• ADME Toxicologists
• Research fellows
• PK/PD modelling
• Toxicologist
• Anatomists
 

AbbVie; Actelion; Astrazeneca; Bayer; BenevolentAI; Corning Life Sciences; Daiichi-Sankyo Europe GmbH; Drugs for Neglected Diseases initiative (DNDi); Galapagos; Galapagos NV; Gedeon Richter; Genentech; GlaxoSmithKline; GSK; Heptares Therapeutics; Imperial College London; Institute of Cancer Research; Japan Tobacco; Merck KGaA; Merck Serono; NESTLE SKIN HEALTH - GALDERMA; Novartis Pharmaceuticals Corporation; Pfizer; Proximagen; Proximagen Group plc; Roche Pharmaceuticals; Sanofi; Sekisui Xenotech LLC; Solvo Biotechnology Inc.; Sygnature Discovery Ltd; Triskelion B.V.; UCB; UCL Institute of Ophthalmology; Vertex Pharmaceuticals;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

9:10 Novel technologies and computational tools in discovery toxicology: opportunities and challenges

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

• Driving nonclinical safety-related attrition to sustainable levels
• Technologies to define target-related safety
• Computational prediction of off-target interactions
• Opportunistic use of in vitro models to tackle complex toxicity issues
 

9:50 How advanced are our in vitro discovery toxicology assays for predicting DILI risks

Timothy Schulz-Utermoehl

Timothy Schulz-Utermoehl, Director of DMPK, Sygnature Discovery Ltd
View Bio

• Generating an understanding as to when predictive in vitro screening should be performed in Discovery
• Use of case studies to qualify the predictability of the available in vitro assays
• Defining if potential metabolites should be screened alongside the active drug
 

10:30 Morning Coffee

11:00 Understanding the correlation between drug exposure, efficacy and toxicity in a transporter mediated drug-drug interaction

Kunal Taskar

Kunal Taskar, Scientific Leader, Mechanistic Safety and Disposition, IVIVT. , GSK
View Bio

• Transporter mediated drug-drug interactions (tDDI) and clinical impact
• Effect on drug  efficacy in a tDDI
• Effect on drug toxicity in a tDDI
• Simultaneous correlation of drug exposure in tDDI with efficacy and toxicity
 

11:40 In vitro study of transporter-mediated DDI’s for regulatory purposes

Roelof Hendrik De Wilde

Roelof Hendrik De Wilde, Director of Sales, Solvo Biotechnology Inc.
View Bio

• Recent FDA guidance changes affecting in vitro drug transporter studies
• Transporter assay calibration to estimate clinical risk
• Study of time dependent inhibition of transporters: beyond FDA recommendations

12:20 Networking Lunch

13:20 Spotlight: The importance of ADMET in medicines regulation: First in human studies and dose-exposure-response analyses

Justin Pittaway-Hay

Justin Pittaway-Hay, Pharmacokinetics Assessor, MHRA
View Bio

• Regulations concerning FIH studies and PBPK modelling and simulation: ADMET considerations
• Importance of demonstrating dose-exposure response relationships
• Extrapolation of PK and role in paediatric populations

 

14:00 Use of early dose prediction and ADMET properties to guide chemical design

Nenad Manevski

Nenad Manevski, DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB
View Bio

• Early dose predictions can be used to guide chemical design and prioritise efforts.  
• Multi-parameter design improves quality of drug-like properties.
• Metabolic stability, permeability, and solubility are linked with toxicological outcomes. 
 

14:40 The use of precision-cut lung slicing model to study pulmonary disposition of a drug

Yildiz Yilmaz

Yildiz Yilmaz, Pharmacokineticist, ADME, Biotransformation, Novartis AG

• Assessment of the pulmonary CYP1A1 metabolism of mavoglurant in rat
• Functional assessment of rat pulmonary Flavin-containing Monooxygenase activity
• Optimization of the precision cut lung slices (PCLS) as a useful tool for assessment of the pulmonary drug disposition in rat and human
 

15:20 Afternoon Tea

15:50 Application of tracer kinetics in drug development: A valuable but underused tool in clinical pharmacology

Pau Aceves

Pau Aceves, Associate Director, Certara Strategic Counselling
View Bio

• Early Phase Drug Development has generally involved the study of pharmacokinetics/pharmacodynamics (PK/PD) under reasonably controlled experimental conditions (eg. known extent and rates of input, use of healthy subjects, etc.)
• We will be exploring the application of alternate quantitative tools: tracers kinetics, and in particular stable label isotope tracers.
• Tracer kinetics analysis allows the study of more than one form of a compound simultaneously thereby opening new opportunities, such as tracing two isoforms of the same drug given by two different routes or obtaining rates of production, pool sizes, and half-life of endogenous substances like amino acids, lipids, DNA and others.
• Attendees will gain insights into how tracer kinetics can be leveraged for PK, PD, and in silico modelling applications and in strategic decision making in early phase drug development
 

16:30 Impact of physical properties of oral drugs on dose and hepatotoxicity

Paul Leeson

Paul Leeson, Director, Paul Leeson Consulting Ltd

• Oral drugs in the upper 20 percentile dose range are on average smaller, less lipophilic, and contain more acids and fewer bases than drugs in the lower 60 percentile dose range
• The overall dose-property trends are consistent with maintaining acceptable safety margins
• A model using dose, Fsp3 and lipophilicity distinguished hepatotoxic from non-hepatotoxic drugs with 82% accuracy and correctly identified 19 of 22 candidates that failed in development due to human hepatotoxicity
• The model is best used preclinically in conjunction with experimental hepatotoxicity mitigation

 

17:10 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Eric Blomme

Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
View Bio

9:10 Hypothesis testing with PBPK to understand if solubility limits in vivo absorption

Sheila Annie Peters

Sheila Annie Peters, Head, Translational Quantitative Pharmacology, Merck Serono
View Bio

• Solubility and dissolution of a drug measured in vitro are often used in PBPK models to understand their in vivo relevance, to assess the need for formulation development, as well as to estimate the effects of food and acid reducing agents (ARA) on the absorption.
• When clinical data following PO administration becomes available, in the absence of IV PK, verification of PBPK model, especially when confounded by gut metabolism and efflux, is difficult to achieve due to parameter non-identifiability.
• This presentation will talk about hypothesis testing with PBPK and how we can employ it for overcoming parameter non-identifiability in order to better predict food and ARA effects on the absorption of an API or a formulation.
 

9:50 Towards a fully PBPK compliant ADME-MOC

Reyk Horland

Reyk Horland, Head of Business Development, TissUse GmbH

•             Introduction to Multi-Organ-on-chip (MOC) solutions
•             The 4-Organ-Chip: A first proof of concept for ADME-studies
•             A PBPK modelling approach for Multi-Organ-Chips
•             Current and future applications
 

10:30 Morning Coffee

11:00 In vitro and In silico tools to predict food-drug interactions

Neil John Parrott

Neil John Parrott, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel

• Pharmacokinetics of drugs can be affected by the physiological changes induced by a meal and so food-effect bioavailability studies are needed to support new drug applications
• The food effect is determined by a compound’s properties and physiologically based pharmacokinetic (PBPK) absorption models integrating drug-specific data are useful predictive tools.
• However regulators currently lack confidence in food effect predictions and cross industry alignment on best practice is needed to support wider confidence.
• A case study will illustrate preclinical and clinical impact for a Roche molecule.
 

11:40 Advances in models for the prediction of human drug metabolism

Ian Wilson

Ian Wilson, Chair, Drug Metabolism and Molecular Toxicology, Imperial College
View Bio

• Avoiding problems in drug development requires good methods for the prediction of drug metabolism/toxicology
• Accurate models that to predict liver-based metabolism in humans human are needed
•  Liver humanized models in rodents based on genetic modification or “chimeric” livers show some promise in this area
•  The pros and cons of the use of each type of systems will be described and illustrated with examples
 

12:20 Networking Lunch

13:20 Interaction of the PI3Kinase inhibitor Taselisib with efflux transporters - In Vivo and In Vitro investigations

Laurent Salphati

Laurent Salphati, Principal Scientist, Genentech, Inc.
View Bio

  • Involvement of efflux transporters in the disposition of Taselisib
  • In vivo investigations of routes of elimination dependent on transporters
  • In vitro studies and relation with clinical findings
     
  • 14:00 Intracellular pharmacokinetics: emerging opportunities for tailoring project support

    Andreas Reichel

    Andreas Reichel, Vice President, Head of Research Pharmacokinetics, Bayer
    View Bio

    • With significant progress in delivery technologies, peptides and peptidomimetics are receiving increasing attention as potential therapeutics for intracellular applications
    • Analyses of the intracellular behaviour of peptides are a challenge making knowledge on the intracellular PK of peptides limited
    • Defining structure–activity relationship of peptides with respect to intracellular residence time and proteolytic breakdown is complex
    • Useful in in vitro efficacy, safety and toxicology testing and a potential link to the optimisation of in-vivo assessments and predictive pharmacology
     

    14:40 Afternoon Tea

    15:10 Use of melanin binding as drug delivery strategy to the posterior eye segment – from concept to reality

    Paulina Jakubiak

    Paulina Jakubiak, PhD Researcher, Roche Pharmaceuticals

    • Short half-life of small molecule drugs in ocular tissues poses the need for developing sustained delivery approaches
    • Melanin binding can be utilized as a retention mechanism at the back of the eye
    • Establishment of an in vitro-in silico technology platform to characterize and predict melanin binding profiles of drug candidates and understand molecular drivers of the binding phenomenon to support rational design of small molecule ophthalmic drugs
    • In vivo relevance assessment – ocular PK studies
     

    15:50 An introduction to breast cancer: from basic science to therapies

    Marie Therese Rached

    Marie Therese Rached, Post-doctoral training fellow, The Institute for Cancer Research, Imperial College London
    View Bio

    • The biology of breast cancer
    • Breast cancer models
    • Signalling pathways and drug discovery
    • Computational biology and drug discovery
     

    16:30 Chairman’s Closing Remarks and Close of Day Two

    Eric Blomme

    Eric Blomme, Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
    View Bio

    +

    FEATURED SPEAKERS

    Eric Blomme

    Eric Blomme

    Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
    Ian Wilson

    Ian Wilson

    Chair, Drug Metabolism and Molecular Toxicology, Imperial College
    Kunal Taskar

    Kunal Taskar

    Scientific Leader, Mechanistic Safety and Disposition, IVIVT. , GSK
    Nenad Manevski

    Nenad Manevski

    DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB
    Pau Aceves

    Pau Aceves

    Associate Director, Certara Strategic Counselling
    Roelof Hendrik De Wilde

    Roelof Hendrik De Wilde

    Director of Sales, Solvo Biotechnology Inc.
    Sheila Annie Peters

    Sheila Annie Peters

    Head, Translational Quantitative Pharmacology, Merck Serono
    Timothy Schulz-Utermoehl

    Timothy Schulz-Utermoehl

    Director of DMPK, Sygnature Discovery Ltd

    Andreas Reichel

    Vice President, Head of Research Pharmacokinetics, Bayer
    Andreas Reichel

    Andreas is Vice President and Head of Research Pharmacokinetics at Bayer Pharmaceuticals Research and Development. His department operates at two sites, Berlin and Wuppertal, and is responsible for the DMPK support of drug discovery projects of all therapeutic areas of Bayer Pharma including cardiology, oncology, and gynaecological therapy.
    Andreas received his PhD in Cell Biology from the University of Leipzig in 1994 studying the regulation of nutrient transport processes at the blood-brain barrier (BBB) in vivo under the supervision of Prof. Armin Ermisch.
    Between 1994 and 1997 he was working in the laboratories of Profs. Joan Abbott and David Begley, King’s College London, where he became interested in in vitro models of the BBB. Funded by several pharmaceutical companies he started working on approaches to assess and predict the CNS penetration of drugs. In 1997, Andreas joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his area of expertise to intestinal and hepatic transport processes and their relevance to drug absorption, drug disposition and drug-induced liver toxicity. In 2000, Andreas joined Schering AG in Berlin where he helped setting up and soon became to lead the department of Research Pharmacokinetics with responsibility for in vitro ADME assays and in vivo PK studies as well as all PK and PK/PD modelling activities to predict the PK and the therapeutic dose in human. After the merger with Bayer in 2006, both RPK departments were combined under his leadership supporting all drug discovery projects of Bayer’s Pharma portfolio starting from lead discovery, through to lead optimisation and candidate selection and profiling, and beyond for both small molecules and biologics.
     

    Eric Blomme

    Vice President Global Pre-Clinical Safety, Senior Research Fellow , AbbVie
    Eric Blomme

    Eric Blomme is Vice President, Global Preclinical Safety at Abbvie Inc. Eric has held several positions at Abbott/AbbVie, including Director Investigative Toxicology and Pathology, Director Integrated Pharmacology, and Project Leader Discovery Advanced Technologies. Prior to joining AbbVie, he worked at Pharmacia and Searle.
    Eric attended the University of Lyon (Doctor in Veterinary Medicine), McGill University (Business School), Cornell University (Residency in Pathology) and The Ohio State University (PhD). Eric is Diplomate of the American College of Veterinary Pathologists. He has published over 70 peer-reviewed manuscripts, multiple editorials, several book chapters, and a book.
     

    Ian Wilson

    Chair, Drug Metabolism and Molecular Toxicology, Imperial College
    Ian Wilson

    Ian D Wilson worked in the pharmaceutical industry for 36 years, most recently as a senior Principal Scientist in the Dept. of Drug Metabolism and Pharmacokinetics at the AstraZeneca research site at Alderley Park in Cheshire, in the UK. In 2012 he moved to Imperial College (London) where he is Professor of Drug metabolism and Molecular Toxicology in the Dept of Surgery and cancer. His research is centred on metabolic phenotyping, drug metabolism, the microbiome and drug bioanalysis, with a particular emphasis on xenobiotic metabolism as a source of adverse drug reactions.

    Justin Pittaway-Hay

    Pharmacokinetics Assessor, MHRA
    Justin Pittaway-Hay

    Justin Hay was conferred his PhD in Medicine (Pharmacology) from the University of Adelaide, Australia in 2007. From March 2007, Justin was in the position of Senior Clinical Scientist at Centre for Human Drug research (CHDR), where he investigated how biomarkers of the central nervous system could be used as a screening tool in early drug development, with a particular interest in analgesics and pain models. In October 2015 he started as Pharmacokinetics Assessor for the Medicines and Healthcare products Agency (MHRA), UK and is a member of the European Medicines Agency’s (EMA's) Modelling and Simulation Working Group (MSWG).

    Kunal Taskar

    Scientific Leader, Mechanistic Safety and Disposition, IVIVT. , GSK
    Kunal Taskar

    Kunal S. Taskar, Ph.D.
    GlaxoSmithKline

    Biosketch

    Kunal Taskar, Ph.D., is currently working as an Associate GSK Fellow and Scientific Leader at GlaxoSmithKline, U.K. in Mechanistic Safety and Disposition, IVIVT R&D department. He is the transporter expert at the GSK UK site and consults on drug transporter related project questions from early drug discovery to post-marketing drug development. His past experience includes working as a drug transporter expert in the DMPK Pharmaceutical Candidate Optimization department at Biocon Bristol-Myers Squibb Research and Development. Kunal completed his doctorate and postdoctoral research at Texas Tech University Health Sciences department, USA, in Quentin Smith’s lab with research focused on drug delivery to central nervous system and role of transporters in drug delivery across the blood-brain barrier (BBB).

    Kunal’s experience and research focus include: drug-drug interaction predictions using PBPK models and mechanistic understanding of the clinically occurring drug–drug interactions; transporter mediated drug delivery and intracellular drug concentrations, especially the role of uptake and efflux transporters in drug pharmacokinetics-pharmacodynamics and disease and toxicology; novel transporters and role in drug disposition (research on critical role of novel transporters at the BBB); improvising current transporter assays and models for drug transporter studies and clinical predictions; and use of endogenous probes for drug mediated transporter modulations.

    Kunal is a member of American Association of Pharmaceutical Scientists (AAPS) and the International Brain Barriers Society. Kunal is also a member of the Predictive Safety Testing Consortium Hepatox-BSEP working group and member of the International Transporter Consortium Whitepaper 2018 effort focused on bile salt export pump transporter.
     

    Laurent Salphati

    Principal Scientist, Genentech, Inc.
    Laurent Salphati

    Dr. Laurent Salphati is currently Principal Scientist in the Drug Metabolism and
    Pharmacokinetics department at Genentech, Inc. He heads the Drug Transporter
    group and has been supporting and leading immunology and oncology project teams
    from preclinical discovery to late stage clinical development. He received his Pharm.D.
    from the University of Paris XI, France, and conducted his Ph.D research,
    investigating the complementary roles of P-glycoprotein and CYP3A in drug
    absorption and disposition, at the University of California, San Francisco under the
    guidance of Dr. Leslie Z. Benet. His research interests include the pharmacokinetics
    and pharmacodynamics of drugs, and the role of drug transporters in drug
    absorption and disposition.
     

    Marie Therese Rached

    Post-doctoral training fellow, The Institute for Cancer Research, Imperial College London
    Marie Therese Rached

    Marie Therese Rached obtained her PhD in metabolic signalling from Imperial College, London. She is currently a senior postdoc investigating signalling pathways in breast cancer within a multidisciplinary team at the Molecular Pathology and Cancer Therapeutics departments, ICR, London.


    Prior to her work in the U.K, she held research positions at Columbia University, New York where she investigated the role of bone as a metabolic organ. She is the recipient of several awards including the ASBMR Young Investigator Award and the Wellcome Trust Fellowship to peruse her PhD.
    She is the author and co-author of a growing number of high-impact scientific papers.
     

    Neil John Parrott

    Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel
    Neil John Parrott

    Nenad Manevski

    DMPK Design Lead, Senior Scientist in Biotransformation and Enzymology, UCB
    Nenad Manevski

    Nenad Manevski is the DMPK Design Lead within Development Sciences at UCB Pharma in Slough, UK. Nenad is part of multi-disciplinary drug design team, closely working with medicinal chemists, toxicologists, and pharmacokineticists to increase drug-likeness of compounds in discovery process. His work strongly relies on application of in silico tools, in vitro – in vivo extrapolations, and early-dose predictions to set priorities and achieve multi-parametric optimisation.


    Pharmacist by training, Nenad received this PhD in Enzymology & Medicinal Chemistry from University of Helsinki, Finland, and did his Postdoc within Biotransformation team of Novartis Institutes for Biomedical Research in Basel, Switzerland. His particular research interests are extrahepatic drug metabolism, aldehyde oxidase, drug design, and applications of early dose predictions. Nenad has authored 10 peer-reviewed publications and presented his work at numerous international meetings in the ADMET field.
     

    Pau Aceves

    Associate Director, Certara Strategic Counselling
    Pau Aceves


    Pau Aceves joined Certara Strategic Consulting in February 2017. Pharmacist by training, and with previous work experience in diverse aspects of the Pharmacy practice—including Community, Clinical and Production Pharmacy—Pau focused his professional career path in the field of Quantitative Clinical Pharmacology (QCP) and PK/PD Modeling & Simulation, since 2006.


    Pau Aceves holds a Master’s Degree in PK/PD Modeling & Simulation from the University of Manchester in the UK. His MSc project was on an Exploratory Quantitaitve Systems Pharmacology Model (QSP) of the Squalene Synthase Inhibitor Lapaquistat Acetate.


    In addition to having worked on QCP-type studies (ie, food effect, bioavailability, DDIs), Pau also has a wide range of experience on other modalities, including: First-in-human (SAD/MAD), Proof-of-mechanism (PoM), Proof-of-concept (PoC), Positron Emission Tomography (PET), and complex combination (or umbrella-type) protocols; as well as experience interacting with regulatory agencies (FDA, EMEA) at various stages of drug development.


    He has a total of 11 years of QCP experience in the design, analysis and reporting of studies in a wide range of therapeutic areas across all phases of drug development. Pau always enjoys devising innovative strategies to streamline and maximize the value of clinical development programmes by combining efficient clinical strategies with fit-for-purpose PK/PD analysis methods, eg, Population PK/PD, Physiologically-based Pharmacokinetic modeling, and Quantitative Systems Pharmacology approaches.
     

    Paul Leeson

    Director, Paul Leeson Consulting Ltd
    Paul Leeson

    Paulina Jakubiak

    PhD Researcher, Roche Pharmaceuticals
    Paulina Jakubiak

    Reyk Horland

    Head of Business Development, TissUse GmbH
    Reyk Horland

    Roelof Hendrik De Wilde

    Director of Sales, Solvo Biotechnology Inc.
    Roelof Hendrik De Wilde

    Roelof de Wilde received his MSc degree in Molecular Biology and Biotechnology from the University of Groningen, the Netherlands. He started his career as Study Director at SOLVO Biotechnology, Budapest, Hungary, where his main responsibility was conducting contract-based research in the lab on drug-membrane transporter interactions. Following this, he provided for several years scientific support for North-American clients as Study Manager. Backed up by his strong technical background and experience working with clients, he was promoted to Director of Sales in 2017, becoming responsible for both the European and Asian-Pacific business development managing a team of several Study- and Account Managers.

    Sheila Annie Peters

    Head, Translational Quantitative Pharmacology, Merck Serono
    Sheila Annie Peters

    Dr. Sheila Annie Peters heads the Translational Quantitative Pharmacology group at Merck Darmstadt. Her areas of expertise in DMPK include Physiologically-based pharmacokinetic (PBPK)-Phamacodynamics (PD) modeling, and PK/PD and drug-drug interactions. Prior to this, she worked at AstraZeneca, Mölndal, where she developed a generic whole-body PBPK model in MATLAB® which she used to support several drug discovery and early development projects across different R&D sites with innovative approaches to identifying potential limitations to drug disposition. She successfully implemented Model-based drug discovery (MBDDx) strategy in Respiratory Inflammation and Autoimmunity iMed through cross-functional collaboration. She won the 2013 IMED (Innovative Medicines) Science Award at AstraZeneca for the “Design and Development of LungSim Simulation tool for Inhalation PK Modelling”. She has published several papers in high impact journals as well as a book on PBPK. As part of the IQ Consortium, she co-authored a White Paper on PBPK along with other experts in industry and continues to work with them on various topics of interest in PBPK.

    Timothy Schulz-Utermoehl

    Director of DMPK, Sygnature Discovery Ltd
    Timothy Schulz-Utermoehl

    Dr Schulz-Utermoehl has over 19 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK & Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and NED of Belfry Therapeutics.

    Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.
     

    Yildiz Yilmaz

    Pharmacokineticist, ADME, Biotransformation, Novartis AG
    Yildiz Yilmaz

    Sponsors

    Official Media Partner

    Supporters

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    2017 Presentation - GENENTECH

    Download

    Speaker Interview Yildiz Yilmaz, Novartis AG

    Download

    Speaker Interview Dr. Eric Blomme, AbbVie

    Download

    Chairmans Invite Letter to ADMET Conference

    Download

    Speaker Interview Nenad Manevski, UCB Pharma

    Download

    Speaker Interview Pau Aceves, Certara Strategic Consulting

    Download

    ADMET 2018 Conference Speakers

    Download

    Brochure Download

    Download

    2017 Presentation - Bayer Pharma Drug Discovery

    Download

    2017 Presentation - Corning Life Science

    Download

    2017 Presentation - GSK

    Download

    PAST ATTENDEE LIST

    Download

    Sponsors


    SOLVO Biotechnology

    Sponsors
    http://www.solvobiotech.com/

    Drug Transporter Services and Products from the Expert! SOLVO Biotechnology is the leading provider of transporter assays Worldwide, since 1999. With over 100 solutions, we support your in-house or outsourced projects with high quality products or services, including FDA-, EMA, PMDA-ready reports.

    Media Partners


    Drug Target Review

    Official Media Partner
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    pharmanews hq

    Official Media Partner
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    MedChemNet

    Official Media Partner
    http://www.medchemnet.com/

    MedChemNet is a unique platform aiming to promote global collaboration between all members of this field, enabling you to make the right connections. As well as access to further exclusive medicinal chemistry articles, regular drug discovery and development news updates, engaging multimedia content and exclusive features, you can connect with peers and follow opinion leaders, while sharing your own insights through blogs and videos to help further the discussion.


    Drug Discovery Today

    Official Media Partner
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Technology Networks

    Official Media Partner
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Samedan

    Official Media Partner
    http://www.samedanltd.com/magazine/13.

    International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.

    Media Partners


    AntibodyChain

    Supporters
    http://www.antibodychain.com

    The complete and transparent marketplace for your research antibodies, kits, proteins and small molecules. The sophisticated search engine, with more than 800.000 products, transparency in suppliers, easy comparison, the one stop shop for your research antibodies in combination with interesting news and events plus a CMO exchange makes us a full service partner for you.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    EIN News

    Supporters
    http://www.einnews.com

    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    CLocate

    Supporters
    http://www.clocate.com

    Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    EBR

    Supporters
    http://www.samedanltd.com

    European BioPharmaceutical Review (EBR) provides a dedicated platform of communication and information for the biopharmaceutical market across Europe, North America and the rest of the world. Each quarterly issue, 10,500 copies of the magazine are distributed to our specially-targeted readership with articles on the hottest topics written by eminent commentators from the biotech scene. www.samedanltd.com


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    BioPharm Insight

    Supporters
    http://www.biopharminsight.com

    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    European Biotechnology Network

    Supporters
    http://european-biotechnology.net/

    The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


    European Pharmaceutical Review

    Supporters
    https://www.europeanpharmaceuticalreview.com/

    European Pharmaceutical Contractor (EPC) is a quarterly publication dedicated to the international pharmaceutical contract market. Since its establishment in 1997, EPC has provided coverage of technical, strategic and regulatory developments within the industry. The magazine features in-depth opinion-led articles, reviews and interviews, on topics including drug development, outsourcing, pharmacovigilance, partnerships and eClinical management. Read EPC in print, online, or via the Samedan app.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out